drugset / Trial / NCT02160067

A Dose Proportionality and Bioavailability Assessment of Buprenorphine Transdermal Delivery System Second Generation Patches

NCT02160067

Phase 1 Completed 20 enrolled Mundipharma Research Limited
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to obtain pharmacokinetic data for a dose proportionality and relative bioavailability assessment of 2nd generation BTDS patches compared to 1st generation BTDS patches.

Timeline

Start
2014-05
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 3.15 mg Other
Subject Buprenorphine Other / unclassified 5 mg Other
Subject Buprenorphine Other / unclassified 12.6 mg Other
Subject Buprenorphine Other / unclassified 20 mg Other

Indications

No indication recorded.